Results 191 to 200 of about 1,454,174 (267)

Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease

, 2011
Cesar Homero Gutiérrez‐Aguirre, Olga Graciela Cantú‐Rodríguez, Omar D. Borjas‐Almaguer, Óscar González‐Llano, J.C. Jaime-Pérez, Manuel Solano-Genesta, Miguel Ángel Gómez‐Guijosa, Consuelo Mancías‐Guerra, Luz Tarin, D. Gomez-Almaguer   +9 more
openalex   +2 more sources

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Crucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples

Molecular Oncology, EarlyView.
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris, Vasiliki Siozopoulou, Léon C van Kempen, Anne Sieben, Ella Roelant, Stig Hellemans, Elyne Backx, Laure Sorber, Koen De Winne, Senada Koljenović, Karen Zwaenepoel   +10 more
wiley   +1 more source

Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer. [PDF]

NPJ Precis Oncol
Arce-Gallego S, Esquefa V, Domenech H, Salca A, Aguilar D, Casals T, Mir G, Simonetti S, Oliveira A, de Llobet L, Neeb A, Brandariz J, Anselmino N, Casanova-Salas I, Herranz N, Serra V, de Bono JS, Mateo J.   +17 more
europepmc   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source

Clinical outcomes of combination therapy for hepatocellular carcinoma in a predominantly hispanic South Texas population. [PDF]

Front Oncol
Hoverson J, Qi J, Mehmken C, Chiu D, Lowry J, Arora SP, Newman N.   +6 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

IGFBP3-mediated effects of an effective combination therapy on HCC. [PDF]

Sci Rep
Chen L, Zhao L, Wu G, Zhang T, Liu Z, Fisher D, Hien NTT, Musabaev E.   +7 more
europepmc   +1 more source

Investigating the comparative effects of six artemisinin-based combination therapies on Plasmodium-induced hepatorenal toxicity

, 2019
Innocent A. Edagha, AritJ Ekpo, EdelungudiI Edagha, J. S. Bassey, TitusP Nyong, AnthonyS Akpan, RoseF Obeten, AnthonyS Okon, BlessingA Ating   +8 more
openalex   +1 more source